How Idiopathic Pulmonary Fibrosis Is Diagnosed and Slowed

Idiopathic pulmonary fibrosis (IPF) is diagnosed by recognizing a specific pattern of lung scarring, called usual interstitial pneumonia (UIP), on a high-resolution CT scan and then agreeing on that reading in a structured multidisciplinary discussion. No blood test and no single biopsy settles it. The 2022 ATS/ERS/JRS/ALAT clinical practice guideline lets a "probable UIP" CT pattern support the diagnosis without surgery when the clinical picture fits. IPF cannot be cured, but two antifibrotic drugs, pirfenidone and nintedanib, each cut the yearly loss of forced vital capacity (FVC) by roughly half in their pivotal trials.

Key points#

• IPF is a diagnosis of exclusion: other causes of lung scarring must be ruled out first.
• The high-resolution CT is sorted into four buckets: UIP, probable UIP, indeterminate, and an alternative diagnosis.
• A "probable UIP" scan in the right patient can now support diagnosis without a surgical biopsy.
• The multidisciplinary discussion, not the scan alone, is where the diagnosis is actually made.
• Pirfenidone and nintedanib slow FVC decline; neither restores lost lung function.

Start with what IPF is not#

Before you can call scarring "idiopathic," you have to earn the word. Idiopathic means no identifiable cause, and that is a conclusion, not a starting point. Fibrosis that looks similar on imaging can come from connective tissue disease, from breathing in mold, birds, or other inhaled triggers over time, from certain medications, and from workplace inhalant risks such as asbestos or silica. Each of these has its own path and, in some cases, its own reversible element. So the first job in an IPF workup is subtraction: history, examination, autoimmune bloodwork, and a careful review of home and work environments, all aimed at removing the alternatives.

IPF itself is a progressive fibrosing disease that usually appears after age 60, more often in men and in people who currently smoke or used to. In the affected lung, scar tissue slowly replaces the thin, elastic walls where oxygen normally crosses into the blood. The lungs stiffen and shrink, breathlessness creeps in with exertion, and a dry cough often tags along. Because the symptoms are generic, the diagnosis leans hard on imaging.

Reading the CT, and why "probable" changed the game#

The 2022 guideline, published by Raghu and colleagues in the American Journal of Respiratory and Critical Care Medicine, asks the radiologist to place the high-resolution CT into one of four categories.

• UIP pattern. Scarring concentrated at the bases and outer edges of the lungs, with honeycombing (clustered small cysts stacked like a honeycomb) and traction bronchiectasis (airways pulled open by surrounding scar).
• Probable UIP. The same base-and-periphery distribution and traction changes, but without definite honeycombing.
• Indeterminate for UIP. Features that neither confirm nor clearly refute the pattern.
• Alternative diagnosis. Findings that point toward another disease entirely.

The subtle but important change in recent guidance is how much weight a "probable UIP" scan now carries. Picture a former smoker in their late sixties with a dry cough, crackles at the lung bases, and no sign of autoimmune or environmental cause. A probable UIP scan in that setting can support a confident IPF diagnosis on its own. That matters because it spares many patients a surgical lung biopsy, an operation that carries real hazard for people whose breathing reserve is already thin.

The diagnosis is made in a room, not on a screen#

A CT report does not diagnose IPF by itself. The guideline puts the multidisciplinary discussion (MDD) at the center of the process. In it, a pulmonologist, a chest radiologist, and a pathologist, joined by a rheumatologist when autoimmune disease is in play, look at the same case together and reconcile any disagreement between the imaging, the labs, and the story the patient tells. Studies consistently show that this format improves agreement between clinicians, and it earns its keep precisely in the difficult cases: a probable or indeterminate scan, or a picture where the imaging and the clinical history pull in different directions. The MDD is also where the group decides whether tissue is needed at all.

When a sample is required, surgery is no longer the only option. In centers with proven experience, transbronchial lung cryobiopsy, which retrieves a small frozen fragment through a bronchoscope, is an accepted alternative to surgical biopsy. The guideline also weighs a genomic classifier, a molecular test that can flag a UIP pattern from tiny samples. Together these tools open more than one route to an answer without always heading to the operating room.

Slowing the slope: what the antifibrotics do#

Once IPF is confirmed, the question shifts from what it is to how fast it moves. Two oral antifibrotics carry the evidence, and it is worth being blunt about what they offer: neither reverses scarring or gives back lost lung. Both slow the rate at which FVC, the standard measure of how much air a person can exhale, falls over time.

Pirfenidone was tested in the phase 3 ASCEND trial (King and colleagues, New England Journal of Medicine, 2014). Over 52 weeks, mean FVC dropped by 235 mL on pirfenidone versus 428 mL on placebo, a relative reduction near 45 percent, and the share of patients who lost 10 percentage points or more of predicted FVC or died fell by roughly 48 percent.

Nintedanib was tested in the twin INPULSIS trials (Richeldi and colleagues, New England Journal of Medicine, 2014). Adjusted annual FVC decline was about 115 mL per year on nintedanib versus roughly 210 to 240 mL per year on placebo across the two studies, again close to a halving in each. Head-to-head, neither drug has proven clearly better than the other, and both come with trade-offs: mainly gastrointestinal effects, especially diarrhea, with nintedanib, and nausea plus skin sensitivity to sunlight with pirfenidone. Guideline recommendations for antifibrotics are conditional, reflecting a benefit that is genuine but partial.

The 2022 update also names a broader category, progressive pulmonary fibrosis, for other fibrosing lung diseases that keep worsening despite treatment. Nintedanib is conditionally recommended there as well, which extends the antifibrotic idea beyond IPF alone.

What "slowing" honestly means#

Halving a decline is not halting it. If you are taking an antifibrotic you are still likely to lose lung function, just at a gentler slope, which over years can mean more time with usable breathing and, in pooled analyses, a hint toward longer survival. The honest promise of these drugs is measured in slope, not in cure. Medication is only part of the plan. Supplemental oxygen, pulmonary rehabilitation, up-to-date vaccinations, treatment of acid reflux and other coexisting conditions, and early, unhurried conversations about lung transplant all shape how well you live the years ahead.

If you are squinting at a scan report or a trial headline, the takeaways are simple. IPF is a pattern read in context, agreed by a team rather than declared by a machine. And its treatment is refreshingly candid: it buys time rather than promising to turn back the clock.